The changes will result in one company focused exclusively on cancer cell therapies and another on strategic transactions to build a pipeline of innovative medicines.

The investment will be used to help increase enrollment of follicular lymphoma patients in an ongoing Phase I study of Verismo's KIR-CAR therapy.

The agency affirmed the use of biopsies for biomarker-driven trials but cautioned against optional biopsies that offer little value to the patient or trial.